38 results about "Immune Cell Activation" patented technology

The invention discloses an engineered exosome preparation with tumor targeting and specific gripper response release functions as well as a preparation method and application of the engineered exosome preparation. The preparation comprises a myocardial cell exosome, an NK cell biotinylation activation antibody, a tumor disease biotinylation antibody, streptavidin, a tumor fiber matrix FAP targeting peptide and a tumor matrix enzyme response peptide, and anchoring is carried out through an acetamide compound-polyethylene glycol anchor point platform. The engineering bispecific exosome preparation with good tumor targeting and barrier breakthrough ability and immune cell activation effect is prepared, and the preparation breaks a solid tumor compact fiber barrier and increases NK cell infiltration by utilizing the fibrosis treatment ability of the myocardial cell exosome and the capture and targeting effects of an anchor point platform; the natural killer cells are in close contact with tumor cells, the lasting tumor cell killing effect is achieved, and the tumor matrix environment is fundamentally changed.

TSLP-TRAPs are a novel class of biologics that have been developed to inhibit the activity of TSLP. By binding to TSLP, TSLP-TRAPS effectively block the interaction between TSLP and its receptor, preventing downstream signaling and immune cell activation. This makes TSLP-TRAPs an attractive therapeutic option for a variety of inflammatory and allergic diseases, including asthma, atopic dermatitis, and eosinophilic esophagitis.

A method for predicting an immune cell activation state is provided, comprising: obtaining a plurality of single immune cell images and a plurality of multiple immune cell images, each immune cell object in the plurality of single immune cell images and the plurality of multiple immune cell images being selected from a set of immune cell objects subjected to a same perturbation condition; processing the plurality of single immune cell images by using a first activation state prediction model to obtain a plurality of first activation state prediction values corresponding to the plurality of single immune cell images respectively, which are output by the first activation state prediction model; processing the plurality of multiple immune cell images by using a second activation state prediction model to obtain a plurality of second activation state prediction values corresponding to the plurality of multiple immune cell images respectively, which are output by the second activation state prediction model; and determining an activation state of the set of immune cell objects based on the plurality of first activation state prediction values and the plurality of second activation state prediction values.

Disclosed herein are immune cells (Bisuper Cells, BS-Cells) that have been engineered to express an immune cell activator polypeptide comprising an extracellular marker domain and incorporate the polypeptide into the cell membrane surface. Also disclosed are immune cells engineered to secrete one or more polypeptide effector molecules, and immune cells engineered to express both molecules. Nucleic acid vectors for expressing these molecules in immune cells are disclosed. Also disclosed are bispecific polypeptides that can be used to specifically bind immune cells expressing immune cell activator polypeptides to another cell. Also disclosed are systems comprising both immune cells and various bispecific polypeptides that can bind to different cell surface proteins of the same or different target cells, e.g., that can be used to expand immune cells in vivo and treat various tumors.

Provided herein are constitutively active chimeric cytokine receptors (CACCRs). Such CACCRs allow for increased immune cell activation, proliferation, persistence, and / or potency when present on immune cells bearing chimeric antigen receptors (CARs). Also provided are methods of making and using the CACCRs described herein.

The application provides development and application of an anti-OX40 antibody and immune cell activation, and the anti-OX40 antibody or a fragment thereof of the application has strong binding to human OX40 or Rhesus monkey OX40.

The present invention relates to the use of an antibody or an immunologically active fragment thereof, which specifically binds to integrin β2, as an immuno-oncology agent. The chimeric and humanized antibodies of the present invention specifically bind to integrin β2, which is a tumor-specific antigen and is expressed on the cell membrane of M2 tumor-associated macrophages, and thus can be used as an antibody therapeutic agent for cancer treatment using a cancer cell death mechanism by immune cell activation, an antibody therapeutic agent for cancer treatment, or a cell therapeutic agent for cancer treatment, and can also be used for cancer diagnosis.

To provide multispecific B7H3 target compounds and methods for using them. [Solution] A multispecific B7H3 target compound and a method of using the same are provided. The multispecific compound includes a bispecific target protein comprising a B7H3 target domain and an immune cell binding domain; and a triplicate target protein comprising a B7H3 target domain, an immune cell binding domain and an immune cell activation domain. The method of use includes a method of inducing NK-mediated cell death, a method of inducing NK expansion in vivo, and a method of treating cancer.

The invention belongs to the technical field of biological medicine, and particularly relates to a rheumatism immune disease treatment composition combining traditional Chinese medicine active ingredients and immune regulation and application of the rheumatism immune disease treatment composition, and the rheumatism immune disease treatment composition comprises the following components in parts by weight: 10-50 parts of a traditional Chinese medicine active ingredient compound; 0.01 to 1 part of an immune regulation factor; 50 to 90 parts of pharmaceutic adjuvants; wherein the traditional Chinese medicine active component compound is prepared from the following components: astragaloside, artemisinin, curcumin and triptolide in a weight ratio of (2-5): (1-3): (1-4): (0.5-2); the immunoregulation factor is composed of recombinant human interleukin-10 (rhIL-10), a transforming growth factor-beta1 (TGF-beta1) and a CTLA4-Ig fusion protein according to a weight ratio of (1-3): (0.5-2): (1-4). The active ingredients of the traditional Chinese medicine cover a plurality of links of anti-inflammation, anti-oxidation, immunoregulation and the like, and immunoregulatory factors accurately intervene in immune cell activation and a cell factor network to jointly inhibit abnormal immune response.

The invention relates to an application of India giant globular bacteria in preparation of a medicine for regulating a tumor microenvironment, and belongs to the technical field of biological medicines. The invention provides an application of India giant globular bacteria XA-511 in preparation of a medicine for regulating a tumor microenvironment. Researches show that the India giant globular bacteria XA-511 can be colonized in a tumor microenvironment, the tumor microenvironment can be transformed through a metabolic pathway of the India giant globular bacteria XA-511, immune cell activation enhancement and the like, and cold tumors are transformed into hot tumors, so that the treatment effect of the immunosuppressor on tumors is promoted. Furthermore, treatment of secondary tumors is more difficult than primary tumors, since tumors may be present at multiple sites, and the volume and number of tumors may vary over time. And by virtue of the characteristic of a tumor hypoxia environment, the India giant globular bacteria XA-511 can be selectively colonized at a tumor occurrence part after entering a systemic circulatory system, so that the tumor microenvironment is specifically changed, and the treatment effect of the immunosuppressor on tumors is enhanced.

The present invention provides the development and application of anti-OX40 antibodies and immune cell activators, and the anti-OX40 antibodies or fragments thereof of the present invention retain relatively strong binding to human OX40 or rhesus monkey OX40.

Disclosed herein, in some aspects, are compositions and methods for enhancing immunosuppressive functions of a cell, polynucleotides encoding polypeptides for effectuating the same, cells comprising the same, and compositions comprising the polypeptides, polynucleotides, and / or cells. In some aspects, the engineered cells show enhanced immunosuppression. Also disclosed are methods for disease treatment, such as graft-versushost disease, sepsis, transplant rejection, and / or autoimmune diseases, comprising administering engineered cells and / or compositions of the disclosure to a subject in need thereof.

The invention relates to a humanized antibody of a targeted human hepatic ligand protein A receptor 10 and application thereof, the specific antibody of the hepatic ligand protein A receptor 10 (EphA10) or a fragment with immunocompetence of the antibody is specifically combined with the EphA10, and the EphA10 is a very promising target spot for overcoming the drug resistance and resistance of the existing immune checkpoint inhibition factor targeted therapeutic agent. And when an ADC is prepared using the antibody, it is shown that it is capable of specifically killing cancer cells, and thus it is useful as an antibody therapeutic agent for treating cancer using a mechanism that causes cancer cell death by immune cell activation, an antibody therapeutic agent for treating EphA10-expressing cancer, or a cell therapeutic agent for treating EphA10-expressing cancer, and it is useful as an antibody therapeutic agent for treating EphA10-expressing cancer. And can also be used for cancer diagnosis.

The present disclosure provides high-performance immune-activation reporter cell line set. A set of nucleic acid constructs comprising one or more response elements operatively linked to a TATA box motif promoter or a minimal IL-2 promoter are provided. A set of reporter cell lines comprising a polynucleotide sequence encoding a reporter protein under the control of one or more response elements operatively linked to a TATA box motif promoter or a minimal IL-2 promoter is also provided. The provided set of reporter cells enable sensitive and signal-enhanced bioassay performance to reflect and evaluate adaptive immune cell activation / inhibition regulated by the immune receptors CD3, co-stimulatory CD28 and related signaling pathways, and avoid responding bias triggered by particular transcription factor. A controllable engineer method for a functional cell line is further provided.

Provided is a pseudotyped viral particle, a viral envelope surface thereof comprising immune cell-targeting molecules and / or immune cell-activating molecules. Corresponding targeting molecules are designed on the basis of cell receptors to be targeted, enabling targeting of different types of cells. The application scope is broad, including but not limited to the rapid preparation of CAR-T, CAR-NK, and other immunotherapeutic cells in vitro without the need for sorting and activation, as well as the direct generation of CAR-T, CAR-NK, and other immunotherapeutic cells in vivo.

The invention discloses an in-vitro amplification method of dog peripheral blood source specific immune cells, and belongs to the technical field of immune cell culture. According to the method, dog peripheral blood serves as a cell source, and efficient amplification of specific immune cells is achieved within 14 days through the steps of lymphocyte separation, immune cell activation, staged density regulation and control culture, culture medium supplementing and the like. By optimizing the combination and concentration of cell factors and accurately regulating and controlling the cell density at different culture stages, the problems of low amplification efficiency, weak specific killing ability, short cell activity maintenance time and the like of the dog immune cells in the prior art are solved. The amplification multiple of the finally obtained specific immune cells can reach 125 times or more, the cell viability is kept 90% or more, the proportion of CD3-NKp46 + phenotype cells exceeds 70%, the application requirements of clinical anti-tumor immune cell preparations can be met, and an efficient and stable cell preparation scheme is provided for dog tumor immunotherapy.

The invention relates to a method of increasing immune cell activation and / or treating cancer in a subject, comprising administering to the subject an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof: H NO R1 ON O R2 O.

The present invention relates to anti-CD137 antigen-binding molecules that have an immune cell-activating effect, cytotoxic activity, or antitumor activity, while simultaneously having a reduced effect on non-tumor tissues, such as normal tissues, and producing fewer side effects, and methods for using the same. Anti-CD137 antigen-binding molecules that have an immune cell-activating effect, cytotoxic activity, or antitumor activity, while simultaneously having a reduced effect on non-tumor tissues, such as normal tissues, and producing fewer side effects, are provided by the discovery and production of CD137 antigen-binding molecules whose CD137-binding activity depends on various substances (e.g., small-molecule compounds) in tissues of interest. Methods for using the same, pharmaceutical formulations, and the like are also provided.An antigen-binding molecule is also provided, whose antigen-binding activity varies depending on the small molecule compound, the method of preparation, and its uses.

Compositions and methods for immunotherapy are provided. In some embodiments, a system for immunotherapy includes: a first composition including an engineered polypeptide conjugated to a small molecule activator, where the engineered polypeptide has a molecular weight less than or equal to 10 kDa, and where the engineered polypeptide binds to a marker on a target cell; and a second composition including an immune cell expressing an engineered receptor that binds to the small molecule activator.

The present disclosure relates to a conjugate of a modified multispecific fusion protein and scFv that binds to an antigen of a binding scFv, a vascular endothelial growth factor and a placental growth factor, and uses thereof. Conjugates according to embodiments of the present disclosure may also exhibit excellent yield and stability. A conjugate according to an embodiment of the present disclosure may exhibit excellent blood stability. The conjugates according to embodiments of the present disclosure may exhibit excellent anti-tumor, anti-fibrosis, and / or immune cell activation effects.

The invention relates to an acoustic-thermal response stent with immunoregulation performance, a preparation method and application. The acoustic-thermal response stent comprises a porous skeleton and a hydrogel material loaded on the porous skeleton, the porous framework is made of an organic polymer material with an acoustic heating effect; the hydrogel material comprises hydrogel, an immune cell activator and gene editing macrophages, wherein the immune cell activator and the gene editing macrophages are loaded on the hydrogel. According to the invention, short-term bacterial removal can be promoted, and a long-term antibacterial and anti-inflammatory microenvironment can be maintained at the same time.

The application relates to a sound-heat response support with immunoregulation performance, a preparation method and application, which comprises a porous framework and a hydrogel material loaded on the porous framework; the porous framework adopts an organic polymer material with a sound-heat effect; the hydrogel material comprises a hydrogel and an immune cell activator and a gene editing macrophage loaded on the hydrogel. The application can promote short-term bacterial clearance and also maintain a long-term antibacterial and anti-inflammatory microenvironment.

This invention provides an immunotherapy regimen for inhibiting tumors, especially solid tumors—combining T cells expressing chimeric CD3e fusion protein with BiTA. The chimeric CD3e fusion protein and BiTA bind to each other, activating T cells and targeting tumor cells. This invention also provides a CAB structure and CAB-edited T cells (CAB-T). BiTA secreted by CAB-T cells in tumor tissue can simultaneously activate CAB-T cells and the endogenous TCRs of non-edited T cells, exerting both CAB-T's own anti-tumor effects and mobilizing the anti-tumor effects of unedited T cells. The chimeric CD3e expressed by CAB-T and BiTA synergistically exert anti-tumor effects: the activation of chimeric CD3e depends on BiTA secreted by CAB-T, and the secretion of BiTA further stimulates CAB-T to release more BiTA by activating chimeric CD3e; the small amount of BiTA released by CAB-T in tumor tissue can stimulate CAB-T to release more BiTA by activating chimeric CD3e, achieving tumor-preferred immune cell activation and anti-tumor effects, ensuring the safety advantage of CAB-T in clinical applications.

The present application provides a compound useful as an effective ingredient of a therapeutic drug composition for a cancer associated with immune cell activation or a cancer resistant to anti-PD-1 antibody / anti-PD-L1 antibody therapy. The present inventors have researched a compound useful as an effective ingredient of a therapeutic drug composition for a cancer associated with immune cell activation or a cancer resistant to anti-PD-1 antibody / anti-PD-L1 antibody therapy, and have confirmed that a heteroaryl formamide compound has DGKζ (DGKzeta) inhibitory action, thereby completing the present application. The heteroaryl formamide compound of the present application has DGKζ inhibitory action, and can be used as a therapeutic agent for a cancer associated with immune cell activation or a cancer resistant to anti-PD-1 antibody / anti-PD-L1 antibody therapy.

A composition of matter comprising at least one fusion polypeptide which comprises a targeting moiety which binds a marker of a myeloid-derived suppressor cell (MDSC) attached to an immune cell-activating cytokine, wherein said immune cell-activating cytokine is masked by a masking agent, such that when said at least one fusion polypeptide is in a vicinity of an MSDC. said masking agent unmasks said immune cell -activating cytokine via an activity of an MSDC- specific protease so as to allow cytokine activity of said immune cell-activating cytokine. Also provided are methods and uses of such a composition for the treatment of cancer.

A pseudotyped viral particle having a Maraba virus envelope glycoprotein or a variant thereof. The surface of the pseudotyped virus envelope comprises an immune cell targeting molecule and / or an immune cell activating molecule. A corresponding targeting molecule is designed according to a cell receptor to be targeted, and can target different types of cells, including immunotherapy cells such as CAR-T and CAR-NK.

Compositions and methods for immunotherapy are provided. In some embodiments, a system for immunotherapy includes: a first composition including an engineered polypeptide conjugated to a small molecule activator, where the engineered polypeptide has a molecular weight less than or equal to 10 kDa, and where the engineered polypeptide binds to a marker on a target cell; and a second composition including an immune cell expressing an engineered receptor that binds to the small molecule activator.

This invention relates to proteins targeting B7H3 and methods of using them. Multispecific B7H3-targeting compounds and methods of using them are provided. These multispecific compounds include bispecific and trispecific targeting proteins. The bispecific targeting protein includes a B7H3 targeting domain and an immune cell binding domain; the trispecific targeting protein includes a B7H3 targeting domain, an immune cell binding domain, and an immune cell activation domain. These methods of use include methods for inducing NK-mediated cell killing, methods for inducing NK cell proliferation in vivo, and methods for treating cancer.

The invention relates to a CD2-overexpressed dual-targeting chimeric antigen receptor and application thereof, and relates to the technical field of biological medicines. The chimeric antigen receptor comprises an antigen binding structural domain, a transmembrane structural domain and an intracellular structural domain, the intracellular structural domain comprises a co-stimulation structural domain and an activation structural domain; the co-stimulatory domain includes CD2. According to the invention, the binding force of CAR-T cells and tumor cells is improved by modifying an extramembrane structure and increasing costimulatory molecules, so that the activation efficiency of CAR immune cells is improved, formation of stable and ordered immune synapses is promoted, and the anti-tumor function of the CAR immune cells is enhanced.

Provided herein are, inter alia, improved materials and methods for obtainment and use of immune cells (e.g., T cells). In particular, the present disclosure provides improved materials and methods of ex vivo immune cell activation, immune cell expansion, and / or enrichment of immune cells, immune cell subsets, and more specifically Vγ9Vδ2 cells. The present disclosure further provides isolated or purified populations of such Vγ9Vδ2 cells, and the ex vivo and in vivo uses thereof. Also provided herein, in various embodiments, are compositions comprising such improved cells, including the isolated or purified populations of such produced Vγ9Vδ2 cells. CAR cells, and the like, and uses of such compositions and cells in treating a subject in need thereof having, for example, a disease or a disorder.